Tech Company Financing Transactions
Diasome Pharmaceuticals Funding Round
On 7/6/2017, Diasome Pharmaceuticals raised $30 million in funding from Medicxi Ventures, Black Beret Life Sciences and JDRF T1D Fund.
Transaction Overview
Company Name
Announced On
7/6/2017
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The investment by Medicxi, JDRF T1D Fund, Black Beret, and McDonald Partners represents a significant validation of Diasome's technology, and we will benefit from their track records of working with and advising successful drug development companies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10000 Cedar Ave. 6
Cleveland, OH 44106
USA
Cleveland, OH 44106
USA
Phone
Website
Email Address
Overview
Diasome Pharmaceuticals, Inc. is a venture-backed biopharmaceutical company focused on novel insulin-based therapies for the improved treatment of diabetes. The Company was formed in 2004 and has completed multiple Phase II human studies of HDV-Insulin, its proprietary insulin targeting system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Geho
Chief Financial Officer
Helga Kautsky
Chief Scientific Officer
Blair Geho
Browse more venture capital transactions:
Prev: 7/6/2017: Light Polymers venture capital transaction
Next: 7/6/2017: URWork venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs